Recent advances in N-glycan biomarker discovery among human diseases  

作　　者：Yi Wang Yuanyuan Liu Si Liu Liming Cheng Xin Liu 

机构地区：[1]Department of Laboratory Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics&Molecular Imaging Key Laboratory,Systems Biology Theme,Department of Biomedical Engineering,College of Life Science and Technology,Huazhong University of Science and Technology,Wuhan 430074,China [3]Department of Epidemiology and Health Statistics,School of Public Health,Fujian Medical University,Fuzhou 350122,China

出　　处：《Acta Biochimica et Biophysica Sinica》2024年第8期1156-1171,共16页生物化学与生物物理学报（英文版）

基　　金：supported by the grants from the National Key Research and Development Program of China(No.2022YFC3400800);the National Natural Science Foundation of China(No.82272418).

摘　　要：N-glycans play important roles in a variety of biological processes.In recent years,analytical technologies with high resolution and sensitivity have advanced exponentially,enabling analysts to investigate N-glycomic changes in different states.Specific glycan and glycosylation signatures have been identified in multiple diseases,including cancer,autoimmune diseases,nervous system disorders,and metabolic and cardiovascular diseases.These glycans demonstrate comparable or superior indicating capability in disease diagnosis and prognosis over routine biomarkers.Moreover,synchronous glycan alterations concurrent with disease initiation and progression provide novel insights into pathogenetic mechanisms and potential treatment targets.This review elucidates the biological significance of N-glycans,compares the existing glycomic technologies,and delineates the clinical performance of N-glycans across a range of diseases.

关 键 词：N-GLYCAN GLYCOMICS BIOMARKER DIAGNOSIS PROGNOSIS 

分 类 号：Q53[生物学—生物化学]